Clinical Trial Update: Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 1/2 dose-escalation trial of abiraterone acetate in hormone-refractory prostate cancer, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostate Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-04-29